drugset / Trial / NCT00928317
Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this clinical trial is to assess the safety, efficacy, tolerability, immunogenicity and pharmacokinetics of 3 dose levels of ART621 in the treatment of rheumatoid arthritis.
Timeline
- Start
- 2009-04
- Primary completion
- 2009-11
- Completion
- 2009-12
Outcome
Outcome not reported
Stopped: “Corporate re-prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PLACULUMAB | Protein / enzyme biologic | 0.75 mg/kg | Subcutaneous |
| Subject | PLACULUMAB | Protein / enzyme biologic | 1.5 mg/kg | Subcutaneous |
| Subject | PLACULUMAB | Protein / enzyme biologic | 3 mg/kg | Subcutaneous |